NOVARTIS INDIA LTD.

Novartis India Ltd has informed the stock exchanges about the physical dispatch of letters to shareholders who have not registered their email addresses. These letters contain the weblink and details for the Annual Report for FY 2025-26, in compliance with SEBI LODR Regulations. The dispatch was managed by their Registrar and Share Transfer Agent, MUFG Intime India Private Limited. The company also reminded shareholders about updating KYC details and the benefits of dematerializing physical securities, referencing recent SEBI circulars.

Novartis India Limited has entered into an Exclusive Promotion and Distribution Agreement with Novartis Healthcare Private Limited (NHPL) for its retina portfolio in India. The agreement, effective September 8, 2026, grants Novartis India the rights to exclusively promote and distribute NHPL's products Accentrix® (ranibizumab) and Pagenax® (brolucizumab). This strategic move marks Novartis India's entry into the ophthalmology therapy area and aims to expand its commercial offerings. The upfront consideration for this agreement is INR 10 Crores. The deal is structured to support the company's growth in a new therapeutic segment.

Novartis India Limited has approved the acquisition of the trademarks 'Minipress' and 'Minipres' registered in India, along with related intellectual property rights, from Pfizer Inc. USA and Pfizer Products Inc. USA. The total aggregate consideration for this transaction is ₹1250,00,10,000 (One Thousand Two Hundred Fifty Crores and Ten Thousand only). The company executed an asset purchase agreement and trademark assignment deeds on September 7, 2026, with the signing and closing occurring simultaneously. The acquired trademarks are for the drug Minipress XL, which treats hypertension and benign prostatic hyperplasia, and recorded revenues of INR 228.6 crores in July 2026 with a 6.3% CAGR over four years.

Novartis India Limited has filed its Annual Report for the financial year 2025-26, along with the Notice of its 78th Annual General Meeting (AGM). The AGM is scheduled for September 24, 2026, to be held via Video Conferencing. The report, which includes the Notice of AGM, is available on the company's website. The company has also detailed the remote e-voting period, which will commence on September 21, 2026, and conclude on September 23, 2026. Members eligible as of September 17, 2026, can participate in remote e-voting, with provisions for e-voting during the AGM itself.

Novartis India Ltd has announced its 78th Annual General Meeting (AGM) will be held on Thursday, September 24, 2026. The meeting will be conducted virtually through Video Conferencing (VC) / Other Audio Visual Means (OAVM), in compliance with regulatory guidelines. The company has also submitted its Annual Report for the financial year 2025-26, which includes the AGM notice. The report is available on the company's website. Remote e-voting will be open from September 21 to September 23, 2026, for shareholders of record as of September 17, 2026.

Novartis India Limited has submitted its Business Responsibility and Sustainability Report (BRSR) for the financial year ended March 31, 2026. The report details the company's initiatives from an Environmental, Social, and Governance (ESG) perspective, aligning with the National Guidelines on Responsible Business Conduct. As a trading entity, Novartis India focuses on pharmaceuticals trading, accounting for 100% of its turnover. The company serves markets nationally, with no export contribution. The BRSR is prepared on a standalone basis and includes disclosures aligned with its promoter, Novartis AG's policies. The report is available on the company's website.

Novartis India Ltd's Board of Directors met on August 17, 2026, approving a new Memorandum of Association to align with the Companies Act, 2013. The board also approved a proposal for a change in the company's name, subject to shareholder approval at the upcoming Annual General Meeting. Amendments to the notice of the 78th AGM were also discussed and approved. The meeting was brief, lasting from 7:15 PM to 7:30 PM IST.

Novartis India Ltd's Board of Directors met on August 7, 2026, approving several key resolutions. These include the adoption of a new Articles of Association, subject to shareholder approval at the upcoming Annual General Meeting. The Board also approved the "Employee Stock Option Plan 2026", pending shareholder consent. Additionally, the company resolved to terminate its Distribution and Promotion Agreement with Dr. Reddy’s Laboratories Limited (DRL), effective September 30, 2026. This termination will allow Novartis India to re-acquire exclusivity and market access for certain products. The notice for the 78th Annual General Meeting was also approved.

Novartis India Limited (NIL) announced that ChrysCapital has acquired a controlling 70.68% stake in the company. This transaction marks ChrysCapital's first majority-controlled investment in the Indian pharmaceutical sector, aiming to build a leading branded-generics platform. Dr. Vikas Gupta has been appointed as the new Managing Director and Chief Executive Officer to lead NIL's next phase of growth. The company, with a legacy in therapeutic areas like pain management and neurosciences, will adopt a new name and corporate identity post-acquisition. ChrysCapital plans to leverage its expertise to strengthen NIL's market position.

Novartis India Ltd's Board of Directors, at its 247th meeting on July 29, 2026, announced the completion of the sale of 17,450,680 equity shares from Novartis AG to WaveRise Investments Limited, ChrysCapital Fund X, and Two Infinity Partners. The Board also approved several key business agreements, including a Tegrital Brand License Deed, a Distribution Agreement with Novartis Pharma Services AG for product distribution in India, and a Trademark Assignment and License Deed. Additionally, Dr. Vikas Gupta was appointed as Additional Director and CEO, with a proposed re-designation to MD & CEO, and Mr. Bhagwat Singh Deora was appointed as Chief Financial Officer, both effective July 29, 2026. The Board also adopted and revised various corporate policies and codes.